Patient foundation accuses rare disease company Taysha of violating licensing agreement
A patient group this summer accused Taysha Gene Therapies of breaching a contract to develop a therapy for an ultra-rare condition, another sign of deep tensions between the company and family foundations.
In July, Hannah’s Hope Fund claimed that Taysha breached a licensing agreement that called for the company to develop a therapy for giant axonal neuropathy, an ultra-rare condition that renders patients quadriplegic and is followed by early death, according to an SEC filing on Tuesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.